Up 113% in a year, guess which ASX 200 healthcare stock just scored another FDA win

The ASX 200 healthcare stock received another FDA approval for its cancer detection product.

| More on:
Cropped shot of an attractive young female scientist working on her computer in the laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

S&P/ASX 200 Index (ASX: XJO) healthcare stock Telix Pharmaceuticals Ltd (ASX: TLX) is marching higher today.

Shares in the diagnostic and therapeutic product developer closed yesterday trading for $27.80. In morning trade on Friday, shares are changing hands for $28.22 apiece, up 1.5%.

This sees the Telix share price up 112.6% since this time last year.

Investors who bought the ASX 200 healthcare stock five years ago, near the trough of the pandemic market sell-off, will now be sitting on gains of 3,143.7%.

Yep. That's no typo.

That's enough to have turned a $5,000 investment on 21 March 2020 into $162,185 today.

And Telix just announced that it has received another approval from the United States Food and Drug Administration (FDA).

Here's what's happening.

ASX 200 healthcare stock gets FDA greenlight

This morning, Telix reported that the FDA has approved its New Drug Application (NDA) for Gozellix, the ASX 200 healthcare stock's next generation PSMA-PET imaging agent for prostate cancer.

According to the release, Gozellix, after radiolabelling with gallium-68 (68-Ga), is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive therapy, and those with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

Telix noted that Gozellix provides a longer shelf life of up to six hours and an extended distribution radius compared to existing gallium-based imaging products.

This means that Gozellix can be delivered much further from its point of production and can, therefore, reach PET cameras that are currently not served by any PSMA imaging providers.

The ASX 200 healthcare stock said this would bring the accuracy and clinical utility of gallium-based imaging to more patients across the US. And with the formulation allowing for more scalable production, Gozellix has the potential to improve the efficiency, scheduling flexibility, and throughput of scanning clinics.

What did management say?

Commenting on the latest FDA approval for the ASX 200 healthcare stock, Telix Precision Medicine CEO Kevin Richardson said, "Securing FDA approval for Gozellix is a major win for prostate cancer patients, who gain enhanced access to state-of-the art 68-Ga PSMA-PET imaging."

Richardson added:

Telix continues to invest in innovation across our portfolio, and Gozellix is a testament to this continuous improvement approach. With the launch of Gozellix, our team is excited to be bringing the new generation of prostate cancer scanning to more American men, delivered with the reliability, service and flexibility that customers have come to expect from Telix.

Telix noted that to date, only a relatively small fraction of the 3.4 million men living with prostate cancer in the US have undergone this type of precision medicine scan.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »